Infigratinib
Showing 1 - 23 of 23
Cholangiocarcinoma, Liver Cancer Trial in Houston (Infigratinib, Atezolizumab, Bevacizumab)
Not yet recruiting
- Cholangiocarcinoma
- Liver Cancer
- Infigratinib
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Aug 18, 2022
Renal Pelvis and Ureter Urothelial Carcinoma Trial in Houston (drug, other, procedure)
Active, not recruiting
- Renal Pelvis and Ureter Urothelial Carcinoma
- Infigratinib
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Jul 21, 2022
Achondroplasia Trial in Australia, Spain, United Kingdom (Infigratinib)
Recruiting
- Achondroplasia
- Infigratinib
-
Parkville, Victoria, Australia
- +3 more
Apr 5, 2022
Achondroplasia Trial in Worldwide (Infigratinib 0.016 mg/kg, Infigratinib 0.032 mg/kg, Infigratinib 0.064 mg/kg)
Recruiting
- Achondroplasia
- Infigratinib 0.016 mg/kg
- +3 more
-
Oakland, California
- +17 more
Apr 5, 2022
Glioma, Glioblastoma, GBM Trial in Chandler, Phoenix, Scottsdale (Infigratinib)
Recruiting
- Glioma
- +2 more
- Infigratinib
-
Chandler, Arizona
- +2 more
Mar 10, 2022
Advanced Malignant Solid Tumor, Cholangiocarcinoma, Metastatic Malignant Solid Tumor Trial in Columbus (Infigratinib)
Recruiting
- Advanced Malignant Solid Neoplasm
- +3 more
- Infigratinib
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Feb 15, 2022
Breast Cancer, HER2-negative Breast Cancer, ER Positive Breast Cancer Trial in Stanford (Infigratinib, Tamoxifen, Omnipaque 350)
Recruiting
- Breast Cancer
- +3 more
- Infigratinib
- +3 more
-
Stanford, CaliforniaStanford University
Feb 16, 2022
Advanced Solid Tumor, CNS Tumor, Recurrent WHO Grade II Glioma Trial in Canada, Germany, United States (Infigratinib)
Not yet recruiting
- Advanced Solid Tumor
- +2 more
- Infigratinib
-
Palo Alto, California
- +9 more
Aug 2, 2022
Bladder Transitional Cell Carcinoma, Bladder Cancer, Fibroblast Growth Factor Receptor Trial (Infigratinib)
Withdrawn
- Bladder Transitional Cell Carcinoma
- +2 more
- Infigratinib
- (no location specified)
Aug 8, 2022
Resectable Intrahepatic Cholangiocarcinoma, Stage 0 Intrahepatic Cholangiocarcinoma AJCC v8, Stage I Intrahepatic
Not yet recruiting
- Resectable Intrahepatic Cholangiocarcinoma
- +4 more
- Cisplatin
- +3 more
-
Atlanta, Georgia
- +2 more
Aug 19, 2022
Advanced Cholangiocarcinoma, FGFR2 Gene Mutation Trial in Worldwide (BGJ398, Gemcitabine, Cisplatin)
Active, not recruiting
- Advanced Cholangiocarcinoma
- FGFR2 Gene Mutation
- BGJ398
- +2 more
-
Gilbert, Arizona
- +115 more
Oct 17, 2022
Upper Tract Urothelial Carcinomas, Urothelial Bladder Cancer Trial in Worldwide (Infigratinib, Placebo)
Recruiting
- Upper Tract Urothelial Carcinomas
- Urothelial Bladder Cancer
- Infigratinib
- Placebo
-
Tucson, Arizona
- +133 more
Apr 25, 2022
FGFR Gene Amplification, FGFR1 Gene Amplification, FGFR2 Gene Amplification Trial in Chicago (BGJ398)
Terminated
- FGFR Gene Amplification
- +9 more
-
Chicago, IllinoisUniversity of Chicago Comprehensive Cancer Center
Apr 9, 2019
Bladder Cancer, Non-Muscle-Invasive Urothelial Carcinoma Trial in New York (BGJ398)
Active, not recruiting
- Bladder Cancer
- Non-Muscle-Invasive Urothelial Carcinoma
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Feb 3, 2022
Tumor With Alterations of the FGF-R Trial in China, Japan (BGJ398)
Completed
- Tumor With Alterations of the FGF-R
-
Guangzhou, Guangdong, China
- +7 more
Dec 6, 2020
Advanced Solid Tumors With Alterations of FGFR1, 2 and or 3, Squamous Lung Cancer With FGFR1 Amplification, Bladder Cancer With
Completed
- Advanced Solid Tumors With Alterations of FGFR1, 2 and or 3
- +5 more
-
Duarte, California
- +49 more
Oct 2, 2019
Tumor-Induced Osteomalacia, Oncogenic Osteomalacia Trial run by the NIDCR (BGJ398)
Terminated
- Tumor-Induced Osteomalacia
- Oncogenic Osteomalacia
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Mar 15, 2021
Advanced Gastrointestinal Stromal Tumor (GIST) Trial in United States (BGJ398, Imatinib Mesylate)
Completed
- Advanced Gastrointestinal Stromal Tumor (GIST)
- BGJ398
- Imatinib Mesylate
-
Boston, Massachusetts
- +6 more
Mar 16, 2020
Solid Tumor, Hematologic Malignancies Trial in United States (BGJ398)
Terminated
- Solid Tumor
- Hematologic Malignancies
-
Birmingham, Alabama
- +55 more
May 28, 2019
Colon Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma Trial in Buffalo (Fluorouracil, Irinotecan
Withdrawn
- Colon Adenocarcinoma
- +16 more
- Fluorouracil
- +5 more
-
Buffalo, New YorkRoswell Park Cancer Institute
May 19, 2016